Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N960

UPID:
CE120_HUMAN

ALTERNATIVE NAMES:
Coiled-coil domain-containing protein 100

ALTERNATIVE UPACC:
Q8N960; Q6AI52; Q6AW89; Q8IWB5; Q8N9Y0; Q8NDE8

BACKGROUND:
The Centrosomal protein of 120 kDa, known alternatively as Coiled-coil domain-containing protein 100, is essential for linking the nucleus with the centrosome via microtubules. It is integral to the regulation of neural progenitor cells' migration, their self-renewal, and the precise positioning of neurons, which are critical for brain development. Additionally, it is necessary for centriole duplication, maturation, and the initiation of ciliogenesis, highlighting its multifaceted role in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Centrosomal protein of 120 kDa could open doors to potential therapeutic strategies. Its involvement in diseases like Short-rib thoracic dysplasia 13 and Joubert syndrome 31 suggests that interventions targeting this protein's pathways could provide relief for patients suffering from these genetic disorders, offering hope for treatments that address both skeletal and neurological manifestations.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.